X
[{"orgOrder":0,"company":"OBiO Technology","sponsor":"Chinagene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OBiO and Chinagene Reached A Strategic Agreement Of Commercial Manufacturing Services For Gene Therapy Products","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CHINA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"OBiO Technology","sponsor":"Refreshgene Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OBiO Announces Strategic Partnership with Refreshgene to Realize Commercialization of Gene Therapy Product","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical"}]
Find Clinical Drug Pipeline Developments & Deals by OBiO Technology
Filters
Companies By Therapeutic Area
Details:
Under the agreement, OBiO leverages its capabilities of process development, large-scale cGMP commercial production and global business development for Refreshgene's RRG-001 gene therapy product.
Lead Product(s):
RRG-001
Therapeutic Area: Ophthalmology
Product Name: RRG-001
Highest Development Status: Preclinical
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Refreshgene Therapeutics
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Agreement
October 24, 2023
Details:
The collaboration aims to accelerate the commercialization of CHINAGENE's ophthalmic gene therapy product ZVS101e. Also OBiO will provide holistic contract development and manufacturing services to CHINAGENE for their gene therapy products.
Lead Product(s):
ZVS101e
Therapeutic Area: Genetic Disease
Product Name: ZVS101e
Highest Development Status: Phase I/ Phase II
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Chinagene
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Collaboration
April 29, 2023